Samsung Biologics

Cell Line and Membrane Global Market Report 2022: Increases in Vaccine Production Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
목요일, 1월 12, 2023
Science, Other Science, Biotechnology, Research, Medical Supplies, Health, Genetics, Other Health, Cell, Physiology, Immortalised cell line, Benchmarking, Porter's five forces analysis, Organic, Risk, Skin, Conditional sentence, Vaccine, Transfection, Growth, Samsung Biologics, Prevalence, Cancer, Fine chemical, Renewable energy

The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.

Key Points: 
  • The global cell line and membrane market was valued at $4,533.04 million in 2021, and is projected to reach $10,574.56 million by 2031, registering a CAGR of 8.8% from 2022 to 2031.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cell line and membrane market analysis from 2021 to 2031 to identify the prevailing cell line and membrane market opportunities.
  • In-depth analysis of the cell line and membrane market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global cell line and membrane market trends, key players, market segments, application areas, and market growth strategies.

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Rising Healthcare Expenditure Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
수요일, 1월 11, 2023
Health, Pharmaceutical, Ankylosing spondylitis, Infliximab, Adalimumab, Ageing, Crohn's disease, Samsung, Psoriasis, Ulcerative colitis, Biogen, Etanercept, Amgen, Growth, Rheumatoid arthritis, Boehringer Ingelheim, Samsung Biologics, Patient, Physician, Pharmacy, Pfizer, Celltrion, Biocon, Investment, Fine chemical, Pet, Novartis

The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.

Key Points: 
  • The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.
  • The adalimumab biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021.
  • The global adalimumab, infliximab and etanercept biosimilars market is concentrated, with a small number of large players in the market.
  • The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026.

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

Retrieved on: 
월요일, 1월 9, 2023
COVID-19, CD8, Cancer, Algorithm, Therapy, RNA transfection, Epitope, Biotechnology, GRNA, Vaccine, Bladder cancer, Partnership, CD4, PBC, Serum Institute of India, Samsung Biologics, Patient, RNA, Research, Abraham Ancer, Shingles, NIH, Green-light

Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.

Key Points: 
  • Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
  • EpiVax Therapeutics was the first personalized vaccine company to use computational tools to identify tolerogenic epitopes in neoantigens and to exclude these from cancer vaccine designs.
  • Together, GreenLight and EpiVax Therapeutics will leverage their respective expertise and jointly develop and commercialize potential novel personalized mRNA-based vaccine candidates for a wide range of oncology indications.
  • “We are delighted to partner with EpiVax Therapeutics, to expedite development of personalized cancer vaccine candidates using GreenLight’s RNA platform,” said Andrey Zarur, CEO of GreenLight.

Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future

Retrieved on: 
수요일, 1월 11, 2023
The Climate Group, Samsung Biologics, Chairperson, Supply, Recycling, Waste management, Task force, Samsung, Energy Task Force, Organization, Corporate Knights, RE100, Magnolia, CDMO, COP27, COP26, Policy, SMI, Nature, KRX, Heart, Health care, Climate change, Carbon, Jony Ive, Majesty, Biodiversity, Mobile phone, Renewable energy, Pharmaceutical industry

The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets.

Key Points: 
  • The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets.
  • The Terra Carta Seal is underpinned by Corporate Knights' Annual Global 100 Top Sustainable Corporations List and the wider principles of the Terra Carta.
  • INCHEON, South Korea, Jan. 10, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), was awarded the Sustainable Markets Initiative's Terra Carta Seal.
  • I congratulate those organizations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets."

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

Retrieved on: 
금요일, 1월 6, 2023
Fordham University, Samsung Biologics, Biotechnology, Knowledge, Journal of Global Drug Policy and Practice, Workforce, Homocystinuria, United, Patient, University, M.B.A, Therapy, University of Texas at Austin, Cystinuria, Vetter Pharma, Management, Psychology, Genentech, Biology

AUSTIN, Texas, Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the company's two clinical programs.

Key Points: 
  • AUSTIN, Texas, Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure.
  • As part of these additional changes, the workforce of the company has been further reduced by approximately 15%.
  • Aeglea is also halting the preclinical work on the Cystinuria and other unnamed pipeline programs.
  • Ms. Caudill joined Aeglea in 2019 and has served as a valued leader of the company's manufacturing, technical operations and pegtarviliase program teams.

Biosimilar Contract Manufacturing Market to Grow More than 100% in the Next 6 Years, The Market will Reach USD 5.5 Billion by 2027 - Arizton

Retrieved on: 
수요일, 12월 14, 2022
Therapy, API, Catalent, Hospital, Prevalence, Samsung Biologics, Biotechnology, CMOS, Original equipment manufacturer, Artificial intelligence, Growth, USD, Pressure, Active ingredient, Acquisition, Pharmaceutical industry, Fine chemical

Check Out Some of the Top-Selling Related Reports:

Key Points: 
  • Check Out Some of the Top-Selling Related Reports:
    Medical Device Contract Manufacturing Market - The global medical device contract manufacturing market size to cross USD 132 billion by 2026, growing at a CAGR of over 10% during the period 2020-2026.
  • Vaccine Contract Manufacturing Market - The global vaccine contract manufacturing market will reach USD 4 billion by 2026, growing at a CAGR of 13% from 2020-2026.
  • North America contributed the highest revenue, with a market share of 35.40% in the global vaccine contract manufacturing market share in 2020.
  • Biopharmaceutical Contract Manufacturing Market The global biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 14.37% from 2022 to 2027.

Biosimilar Contract Manufacturing Market to Grow More than 100% in the Next 6 Years, The Market will Reach USD 5.5 Billion by 2027 - Arizton

Retrieved on: 
수요일, 12월 14, 2022
Therapy, API, Catalent, Hospital, Prevalence, Samsung Biologics, Biotechnology, CMOS, Original equipment manufacturer, Artificial intelligence, Growth, USD, Pressure, Active ingredient, Acquisition, Pharmaceutical industry, Fine chemical

Check Out Some of the Top-Selling Related Reports:

Key Points: 
  • Check Out Some of the Top-Selling Related Reports:
    Medical Device Contract Manufacturing Market - The global medical device contract manufacturing market size to cross USD 132 billion by 2026, growing at a CAGR of over 10% during the period 2020-2026.
  • Vaccine Contract Manufacturing Market - The global vaccine contract manufacturing market will reach USD 4 billion by 2026, growing at a CAGR of 13% from 2020-2026.
  • North America contributed the highest revenue, with a market share of 35.40% in the global vaccine contract manufacturing market share in 2020.
  • Biopharmaceutical Contract Manufacturing Market The global biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 14.37% from 2022 to 2027.

Biologics Contract Development Global Market Report 2022: Advanced Technologies for Biological Production Boost Sector Growth - ResearchAndMarkets.com

Retrieved on: 
수요일, 12월 7, 2022
Science, Other Science, Research, Biotechnology, Thermo Fisher Scientific, Revenue, Product-service system, WuXi Biologics, Protein, EMA, Cancer, Research, Samsung Biologics, FDA, Cros, Incidence, A-DNA, COVID-19, Vaccine, STC, USD, Fine chemical

The Biologics Contract Development Market size is expected to reach USD 13.22 billion by 2030, according to a new study.

Key Points: 
  • The Biologics Contract Development Market size is expected to reach USD 13.22 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.
  • The market is being driven by factors such growing use of advanced technologies for biological production, increased R&D activities by pharmaceutical and biopharma businesses, and supportive regulations for clinical trials in developing nations.
  • The publisher has segmented the biologics contract development market report based on source, product service, indication, and region:
    Biologics Contract Development, Source Outlook (Revenue - USD Billion, 2018 - 2030)

Biologics Outsourcing Global Market Report 2022: Advanced Bioprocessing Capabilities of Bioservice Providers Driving Growth - ResearchAndMarkets.com

Retrieved on: 
금요일, 11월 18, 2022
Health, General Health, Samsung Biologics, Prevalence, Cros, LNP, Biotechnology, Degenerative disease, Cognate, Partnership, Infection, CDMO, DNA, CGT, Acquisition, RNA transfection, A-DNA, Curia, Geography, Therapy, RNA, Organization, Vaccine, Fine chemical, Pharmaceutical industry

The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030.

Key Points: 
  • The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030.
  • Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars.
  • The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography.
  • Based on the phase, biologics outsourcing global market segmented into discovery, pre-clinical, clinical and commercial phases of biologics development.

Seven pharma CEOs announce new joint action to accelerate net zero healthcare

Retrieved on: 
목요일, 11월 3, 2022
Other Health, Professional Services, Pharmaceutical, Sustainability, Technology, Environment, Health Technology, Biotechnology, Other Technology, Climate Change, Environmental, Social and Governance (ESG), Health, Online, Mortality, Awareness, UNICEF, World, Air pollution, World Health Organization, Overalls, Malnutrition, Merck Group, WHO, COP26, Middle Class Working Families Task Force, LCA, Global health, Harm, Health minister, Health, Mental health, AstraZeneca, Health policy, Climate, Lancet, SMI, Novo Nordisk, Samsung Biologics, Risk, Partnership, Roche, GSK, Infection, Link, Climate change, Carbon, Task force, Pharmaceutical industry, Medical device, Renewable energy, Sanofi, Guardian

CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi today announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

Key Points: 
  • CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi today announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
  • The Task Force is taking scalable action to collectively address emissions across supply chains, patient care pathways, and clinical trials.
  • During the pandemic, the healthcare sector stepped up and showed what can be achieved when we work together.
  • To support health systems stakeholders accelerate towards net zero, the Task Force has today published three whitepapers outlining practical recommendations and scalable actions:
    World Health Organization.